News | February 03, 2025
Jubilant Pharmova Q3 FY25 revenue up 9%
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
US Generics grew 5% to Rs. 467 Crores for the quarter
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Subscribe To Our Newsletter & Stay Updated
